NCT00234507

Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm

Phase II, Multi-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Administration, by Subcutaneous Injection, of Three Doses of Dysport (40 Units/Eye, 80 Units/Eye, and 120 Units/Eye) for the Treatment of Benign Essential Blepharospasm

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.

Conditions

• Blepharospasm

Interventions

Type	Name	Description
BIOLOGICAL	Botulinum toxin type A

Timeline

• Start date: 2003-01-01
• Primary completion: 2004-05-25
• Completion: 2004-05-25
• First posted: 2005-10-07
• Last updated: 2019-07-29

Locations

14 sites across 1 country: United States